2770 studies found for:    paclitaxel
Show Display Options
Rank Status Study
1 Active, not recruiting Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Condition: Resectable Pancreatic Adenocarcinoma
Interventions: Drug: LDE-225;   Drug: Gemcitabine;   Drug: nab-paclitaxel
2 Recruiting A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
Condition: Advanced Cancer
Interventions: Drug: AZD2014 3 on/4 off & weekly paclitaxel;   Drug: AZD2014 2 on/5 off & weekly paclitaxel
3 Active, not recruiting BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin;   Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin;   Drug: BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1);   Drug: BKM120, Paclitaxel + Carboplatin
4 Not yet recruiting Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: Enzalutamide;   Drug: Carboplatin;   Drug: Paclitaxel
5 Recruiting Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel
Conditions: Ovarian Cancer;   Endometrial Cancer;   Cervical Cancer;   Breast Cancer Triple Negative
Intervention: Drug: ARQ 092 + carboplatin + paclitaxel
6 Withdrawn A Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: Intraperitoneal tgDCC-E1A;   Drug: Paclitaxel
7 Not yet recruiting Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Conditions: Fallopian Tube Carcinoma;   Recurrent Ovarian Cancer;   Primary Peritoneal Carcinoma;   Recurrent Endometrial Cancer
Interventions: Drug: Lenvatinib Mesylate;   Drug: Paclitaxel;   Other: Pharmacological Study
8 Completed PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: Dasatinib, Paclitaxel, and Carboplatin
9 Active, not recruiting Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Condition: Metastatic Breast Cancer
Interventions: Drug: U3-1287;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Placebo
10 Terminated Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: Intraperitoneal tgDCC-E1A;   Drug: Paclitaxel
11 Recruiting Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Condition: Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Trastuzumab;   Drug: Pertuzumab
12 Completed Hepatic Arterial Infusion (HAI) of Abraxane
Conditions: Liver Cancer;   Advanced Cancers;   Solid Tumors
Interventions: Drug: HAI Abraxane;   Procedure: Hepatic Artery Catheter;   Drug: IV Abraxane
13 Active, not recruiting Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
14 Completed Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer
Condition: Advanced Pancreatic Cancer
Interventions: Drug: Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4;   Drug: Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4;   Drug: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4;   Drug: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
15 Recruiting Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab®-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: nab-paclitaxel IV;   Drug: CC-486
16 Active, not recruiting Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer.
Intervention: Drug: nab-Paclitaxel
17 Completed Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine plus nab-paclitaxel
18 Recruiting Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Pancreatic Neoplasms
Interventions: Drug: nab-Paclitaxel;   Drug: Nivolumab;   Drug: Gemcitabine;   Drug: Carboplatin
19 Recruiting Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: MPDL3280A;   Drug: Nab-paclitaxel
20 Recruiting Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments
Condition: Solid Tumors
Interventions: Drug: Paclitaxel liposome injection;   Drug: Paclitaxel injection

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years